MA27001A1 - Derives spirotricycliques nouveaux et leur utilisation comme inhibiteurs de phospho-diesterase-7 - Google Patents

Derives spirotricycliques nouveaux et leur utilisation comme inhibiteurs de phospho-diesterase-7

Info

Publication number: MA27001A1
Authority: MA; Morocco
Prior art keywords: diesterase; phospho; inhibitors; novel; spirotricyclic
Prior art date: 2001-03-21

Application number

MA27310A

Other languages

English (en)

Inventor

Edwige Lorthiois

Pierre Ducrot

Fabrice Vergne

Patrick Bernardelli

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-21

Filing date

2003-09-12

Publication date

2004-12-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8164349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27001(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-09-12 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2004-12-20 Publication of MA27001A1 publication Critical patent/MA27001A1/fr

Links

239000002606 phosphodiesterase VII inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

MA27310A 2001-03-21 2003-09-12 Derives spirotricycliques nouveaux et leur utilisation comme inhibiteurs de phospho-diesterase-7 MA27001A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/EP2001/003355 WO2002076953A1 (fr)	2001-03-21	2001-03-21	Nouveaux derives spirotricycliques et utilisation de ces derives en tant qu'inhibiteurs de la phosphodiesterase-7

Publications (1)

Publication Number	Publication Date
MA27001A1 true MA27001A1 (fr)	2004-12-20

Family

ID=8164349

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA27310A MA27001A1 (fr)	2001-03-21	2003-09-12	Derives spirotricycliques nouveaux et leur utilisation comme inhibiteurs de phospho-diesterase-7

Country Status (46)

Country	Link
US (3)	US20020198198A1 (fr)
EP (2)	EP1801106A3 (fr)
JP (1)	JP4086663B2 (fr)
KR (1)	KR100617435B1 (fr)
CN (1)	CN100447136C (fr)
AP (1)	AP1699A (fr)
AR (1)	AR033617A1 (fr)
AT (1)	ATE367381T1 (fr)
AU (1)	AU2002304800B2 (fr)
BG (1)	BG108181A (fr)
BR (1)	BR0208192A (fr)
CA (1)	CA2441313C (fr)
CU (1)	CU23218A3 (fr)
CY (1)	CY1106829T1 (fr)
CZ (1)	CZ20032451A3 (fr)
DE (1)	DE60221233T2 (fr)
DK (1)	DK1373224T3 (fr)
EA (1)	EA006815B1 (fr)
EC (1)	ECSP034750A (fr)
EE (1)	EE200300459A (fr)
ES (1)	ES2288552T3 (fr)
GE (1)	GEP20053631B (fr)
GT (1)	GT200200053A (fr)
HR (1)	HRP20030740A2 (fr)
HU (1)	HUP0303637A3 (fr)
IL (2)	IL157659A0 (fr)
IS (1)	IS2529B (fr)
MA (1)	MA27001A1 (fr)
MX (1)	MXPA03008485A (fr)
MY (1)	MY142045A (fr)
NO (1)	NO326086B1 (fr)
NZ (1)	NZ527847A (fr)
OA (1)	OA12454A (fr)
PA (1)	PA8541601A1 (fr)
PE (1)	PE20021010A1 (fr)
PL (1)	PL367058A1 (fr)
PT (1)	PT1373224E (fr)
RS (1)	RS50429B (fr)
SI (1)	SI1373224T1 (fr)
SK (1)	SK11562003A3 (fr)
SV (1)	SV2003000925A (fr)
TN (1)	TNSN03076A1 (fr)
TW (1)	TWI267509B (fr)
UA (1)	UA74243C2 (fr)
WO (2)	WO2002076953A1 (fr)
ZA (1)	ZA200306601B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1400244A1 (fr) *	2002-09-17	2004-03-24	Warner-Lambert Company LLC	Nouveaux quinazolinones spirocondensés et leur utilisation comme inhibiteurs de la phosphodiesterase
GB0230195D0 (en) *	2002-12-24	2003-02-05	Biofocus Plc	Compound Libraries
EP1622569B1 (fr)	2003-04-24	2015-12-02	Incyte Corporation	Derives d'aza spiro alcane en tant qu'inhibiteurs de metalloproteases
JP2006219374A (ja)	2003-06-13	2006-08-24	Daiichi Asubio Pharma Co Ltd	Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
JP2006219373A (ja)	2003-06-13	2006-08-24	Daiichi Asubio Pharma Co Ltd	Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
WO2005013997A1 (fr) *	2003-08-12	2005-02-17	F. Hoffmann-La Roche Ag	Tetrahydroquinazolines spiro-substituees utilisees en tant qu'antagonistes du facteur de liberation de la corticotrophine (crf)
DK2433943T3 (da)	2004-07-01	2013-12-16	Daiichi Sankyo Co Ltd	Mellemprodukter til thienopyrazol-derivater med PDE7-inhibitorisk aktivitet
EP1855686A1 (fr) *	2005-03-01	2007-11-21	Pfizer Limited	Utilisation des inhibiteurs de pde7 pour le traitement de la douleur neuropathique
WO2006092692A1 (fr) *	2005-03-01	2006-09-08	Pfizer Limited	Utilisation d'associations d’inhibiteurs de pde7 et de ligands alpha-2-delta pour le traitement de la douleur neuropathique
GB0504209D0 (en) *	2005-03-01	2005-04-06	Pfizer Ltd	New use of PDE7 inhibitors
KR100680497B1 (ko) *	2005-07-25	2007-02-08	엘지전자 주식회사	근거리통신 시스템에서 단말기가 액세스 포인트에 접속하는방법
EP2258357A3 (fr)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenèse avec inhibiteur de l'acetylcholinestérase
EP2275096A3 (fr)	2005-08-26	2011-07-13	Braincells, Inc.	Neurogenese par modulation des recepteurs muscariniques
WO2007047978A2 (fr)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation de la neurogenese par inhibition de la pde
EP2314289A1 (fr)	2005-10-31	2011-04-27	Braincells, Inc.	Modulation de la neurogenese dont la médiation est assurée par récepteur gaba
US8067433B2 (en)	2005-11-09	2011-11-29	Zalicus Inc.	Methods, compositions, and kits for the treatment of ophthalmic disorders
WO2007063391A2 (fr)	2005-12-02	2007-06-07	Pfizer Limited	Derives spirocycliques
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2021000A2 (fr)	2006-05-09	2009-02-11	Braincells, Inc.	Neurogenèse par modulation de l'angiotensine
US7678808B2 (en)	2006-05-09	2010-03-16	Braincells, Inc.	5 HT receptor mediated neurogenesis
WO2008030651A1 (fr) *	2006-09-08	2008-03-13	Braincells, Inc.	Combinaisons contenant un dérivé de 4-acylaminopyridine
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
US8637528B2 (en)	2007-03-27	2014-01-28	Omeros Corporation	Use of PDE7 inhibitors for the treatment of movement disorders
MX2009010450A (es)	2007-03-27	2009-11-23	Omeros Corp	El uso de inhibidores de la fosfodiesterasa 7 para el tratamiento transtornos del movimiento.
CA2687944A1 (fr) *	2007-05-24	2008-11-27	Pfizer Limited	Derives spirocycliques
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
US9220715B2 (en)	2010-11-08	2015-12-29	Omeros Corporation	Treatment of addiction and impulse-control disorders using PDE7 inhibitors
KR102385359B1 (ko)	2010-11-08	2022-04-11	오메로스 코포레이션	Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
WO2012088266A2 (fr)	2010-12-22	2012-06-28	Incyte Corporation	Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
WO2013106547A1 (fr)	2012-01-10	2013-07-18	President And Fellows Of Harvard College	Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
CA2876689C (fr)	2012-06-13	2022-04-26	Incyte Corporation	Composes tricycliques substitues utilises comme inhibiteurs de fgfr
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
PH12015502383B1 (en)	2013-04-19	2023-02-03	Incyte Holdings Corp	Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
CA2976790C (fr)	2015-02-20	2024-02-27	Incyte Corporation	Heterocycles bicycliques utilises en tant qu'inhibiteurs de fgfr
US9580423B2 (en)	2015-02-20	2017-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
RU2753696C2 (ru) *	2015-12-16	2021-08-19	Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд.	Аналог пиридо[1,2-a]пиримидона, его кристаллическая форма, его промежуточное соединение и способ их получения
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN107382976A (zh) *	2017-07-04	2017-11-24	孙秀芹	一种治疗盆腔炎的化合物及制备方法和应用
US11685745B2 (en)	2017-07-12	2023-06-27	Dart Neuroscience, Llc	Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors
RS66310B1 (sr)	2018-05-04	2025-01-31	Incyte Corp	Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
KR102956194B1 (ko)	2018-05-04	2026-04-23	인사이트 코포레이션	Fgfr 억제제의 염
WO2020185532A1 (fr)	2019-03-08	2020-09-17	Incyte Corporation	Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
WO2021007269A1 (fr)	2019-07-09	2021-01-14	Incyte Corporation	Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
US12122767B2 (en)	2019-10-01	2024-10-22	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en)	2019-10-14	2024-10-10	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en)	2019-10-16	2023-01-31	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2021113479A1 (fr)	2019-12-04	2021-06-10	Incyte Corporation	Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
MX2022006691A (es)	2019-12-04	2022-09-19	Incyte Corp	Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
US12012409B2 (en)	2020-01-15	2024-06-18	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
EP4323405A1 (fr)	2021-04-12	2024-02-21	Incyte Corporation	Polythérapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4
CA3220274A1 (fr)	2021-06-09	2022-12-15	Incyte Corporation	Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
TW202313610A (zh)	2021-06-09	2023-04-01	美商英塞特公司	作為ｆｇｆｒ抑制劑之三環雜環
CA3264513A1 (fr)	2022-08-18	2024-02-22	Mitodicure Gmbh	Utilisation de composés de benzofurane et de benzoxazole substitués pour le traitement et la prévention de maladies associées à la fatigue chronique, à l'épuisement et/ou à l'intolérance à l'effort

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5815979A (ja)	1981-07-11	1983-01-29	Kyowa Hakko Kogyo Co Ltd	新規なピペリジン誘導体およびその製造法
US4764512A (en)	1986-08-27	1988-08-16	Rorer Pharmaceutical Corporation	Benzodiazinone-pyridone compounds, cardiotonic compositions including the same, and their uses
GR1000821B (el) *	1988-11-22	1993-01-25	Tanabe Seiyaku Co	Μεθοδος παραγωγης παραγωγων κιναζολινονης.
SK282166B6 (sk)	1992-12-11	2001-11-06	Merck & Co., Inc.	Spiropiperidínové deriváty, spôsob ich výroby a farmaceutický prostriedok s ich obsahom
US5578593A (en) *	1992-12-11	1996-11-26	Merck & Co., Inc.	Spiro piperidines and homologs promote release of growth hormone
US5602143A (en) *	1994-12-08	1997-02-11	Allergan	Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
EE9800116A (et) *	1995-10-17	1998-10-15	Astra Pharmaceuticals Limited	Farmatseutiliselt aktiivsed kinasoliini ühendid
CN1205008A (zh) *	1996-08-30	1999-01-13	协和发酵工业株式会社	咪唑并喹唑啉衍生物
US6498154B1 (en)	1999-05-04	2002-12-24	Wyeth	Cyclic regimens using quinazolinone and benzoxazine derivatives
US6509334B1 (en)	1999-05-04	2003-01-21	American Home Products Corporation	Cyclocarbamate derivatives as progesterone receptor modulators
WO2000066560A1 (fr) *	1999-05-04	2000-11-09	American Home Products Corporation	Derives de quinazolinone et de benzoxazine tenant lieu de modulateurs du recepteur de progesterone
ES2226833T3 (es)	1999-05-04	2005-04-01	Wyeth	Composiciones anticonceptivas que contienen agentes antiprogestinicos y progestinicos.
US6358948B1 (en) *	1999-05-04	2002-03-19	American Home Products Corporation	Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
WO2001045707A1 (fr)	1999-12-21	2001-06-28	Merck & Co., Inc.	Inhibiteurs de prenyl-proteine transferase
UA73119C2 (en)	2000-04-19	2005-06-15	American Home Products Corpoir	Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors

2001
- 2001-03-21 WO PCT/EP2001/003355 patent/WO2002076953A1/fr not_active Ceased
- 2001-03-21 AP APAP/P/2003/002857A patent/AP1699A/en active
2002
- 2002-03-05 TW TW091104028A patent/TWI267509B/zh not_active IP Right Cessation
- 2002-03-18 BR BR0208192-0A patent/BR0208192A/pt not_active IP Right Cessation
- 2002-03-18 PL PL02367058A patent/PL367058A1/xx not_active Application Discontinuation
- 2002-03-18 MX MXPA03008485A patent/MXPA03008485A/es active IP Right Grant
- 2002-03-18 PT PT02732544T patent/PT1373224E/pt unknown
- 2002-03-18 HR HR20030740A patent/HRP20030740A2/hr not_active Application Discontinuation
- 2002-03-18 EE EEP200300459A patent/EE200300459A/xx unknown
- 2002-03-18 NZ NZ527847A patent/NZ527847A/en unknown
- 2002-03-18 AU AU2002304800A patent/AU2002304800B2/en not_active Ceased
- 2002-03-18 ES ES02732544T patent/ES2288552T3/es not_active Expired - Lifetime
- 2002-03-18 HU HU0303637A patent/HUP0303637A3/hu unknown
- 2002-03-18 AT AT02732544T patent/ATE367381T1/de not_active IP Right Cessation
- 2002-03-18 CN CNB028069714A patent/CN100447136C/zh not_active Expired - Fee Related
- 2002-03-18 EA EA200300906A patent/EA006815B1/ru unknown
- 2002-03-18 DK DK02732544T patent/DK1373224T3/da active
- 2002-03-18 TN TNPCT/EP2002/003594A patent/TNSN03076A1/fr unknown
- 2002-03-18 DE DE60221233T patent/DE60221233T2/de not_active Expired - Lifetime
- 2002-03-18 MY MYPI20020954A patent/MY142045A/en unknown
- 2002-03-18 SI SI200230587T patent/SI1373224T1/sl unknown
- 2002-03-18 CA CA002441313A patent/CA2441313C/fr not_active Expired - Fee Related
- 2002-03-18 KR KR1020037012247A patent/KR100617435B1/ko not_active Expired - Fee Related
- 2002-03-18 SK SK1156-2003A patent/SK11562003A3/sk not_active Application Discontinuation
- 2002-03-18 JP JP2002573763A patent/JP4086663B2/ja not_active Expired - Fee Related
- 2002-03-18 WO PCT/EP2002/003594 patent/WO2002074754A1/fr not_active Ceased
- 2002-03-18 EP EP07104642A patent/EP1801106A3/fr not_active Withdrawn
- 2002-03-18 IL IL15765902A patent/IL157659A0/xx active IP Right Grant
- 2002-03-18 UA UA2003098601A patent/UA74243C2/uk unknown
- 2002-03-18 OA OA1200300226A patent/OA12454A/en unknown
- 2002-03-18 EP EP02732544A patent/EP1373224B1/fr not_active Expired - Lifetime
- 2002-03-18 RS YUP-740/03A patent/RS50429B/sr unknown
- 2002-03-18 CZ CZ20032451A patent/CZ20032451A3/cs unknown
- 2002-03-18 GE GE5294A patent/GEP20053631B/en unknown
- 2002-03-19 US US10/101,996 patent/US20020198198A1/en not_active Abandoned
- 2002-03-20 AR ARP020100993A patent/AR033617A1/es active IP Right Grant
- 2002-03-20 SV SV2002000925A patent/SV2003000925A/es not_active Application Discontinuation
- 2002-03-20 PE PE2002000212A patent/PE20021010A1/es not_active Application Discontinuation
- 2002-03-20 PA PA20028541601A patent/PA8541601A1/es unknown
- 2002-03-20 GT GT200200053A patent/GT200200053A/es unknown
2003
- 2003-08-25 ZA ZA200306601A patent/ZA200306601B/en unknown
- 2003-08-27 EC EC2003004750A patent/ECSP034750A/es unknown
- 2003-08-28 IL IL157659A patent/IL157659A/en not_active IP Right Cessation
- 2003-08-29 CU CU20030188A patent/CU23218A3/es not_active IP Right Cessation
- 2003-08-29 IS IS6934A patent/IS2529B/is unknown
- 2003-09-12 MA MA27310A patent/MA27001A1/fr unknown
- 2003-09-17 BG BG108181A patent/BG108181A/xx unknown
- 2003-09-19 NO NO20034187A patent/NO326086B1/no not_active IP Right Cessation
2004
- 2004-05-24 US US10/852,404 patent/US7214676B2/en not_active Expired - Fee Related
2006
- 2006-10-20 US US11/551,687 patent/US20070049558A1/en not_active Abandoned
2007
- 2007-08-30 CY CY20071101121T patent/CY1106829T1/el unknown

Also Published As

Publication number	Publication date
TWI267509B (en)	2006-12-01
US20040214843A1 (en)	2004-10-28
US20020198198A1 (en)	2002-12-26
AU2002304800B2 (en)	2007-08-30
GT200200053A (es)	2003-02-12
EE200300459A (et)	2004-02-16
NO20034187D0 (no)	2003-09-19
WO2002074754A1 (fr)	2002-09-26
EP1373224B1 (fr)	2007-07-18
CN1498212A (zh)	2004-05-19
EP1801106A3 (fr)	2007-07-04
PT1373224E (pt)	2007-09-25
HUP0303637A3 (en)	2004-07-28
CN100447136C (zh)	2008-12-31
KR20030086315A (ko)	2003-11-07
NO20034187L (no)	2003-10-15
EP1801106A2 (fr)	2007-06-27
AP1699A (en)	2006-12-26
BG108181A (bg)	2004-09-30
WO2002076953A1 (fr)	2002-10-03
IS6934A (is)	2003-08-29
YU74003A (sh)	2006-05-25
JP2004529123A (ja)	2004-09-24
HK1061854A1 (zh)	2004-10-08
US7214676B2 (en)	2007-05-08
UA74243C2 (uk)	2005-11-15
EP1373224A1 (fr)	2004-01-02
AP2003002857A0 (en)	2003-09-30
DE60221233T2 (de)	2008-04-03
NZ527847A (en)	2005-06-24
AR033617A1 (es)	2003-12-26
KR100617435B1 (ko)	2006-08-31
US20070049558A1 (en)	2007-03-01
TNSN03076A1 (fr)	2005-12-23
ES2288552T3 (es)	2008-01-16
ZA200306601B (en)	2004-08-25
PE20021010A1 (es)	2003-02-01
NO326086B1 (no)	2008-09-15
MY142045A (en)	2010-08-30
MXPA03008485A (es)	2003-12-08
DK1373224T3 (da)	2007-10-15
JP4086663B2 (ja)	2008-05-14
IS2529B (is)	2009-07-15
RS50429B (sr)	2009-12-31
PL367058A1 (en)	2005-02-21
ECSP034750A (es)	2003-10-28
GEP20053631B (en)	2005-10-10
CU23218A3 (es)	2007-07-20
ATE367381T1 (de)	2007-08-15
PA8541601A1 (es)	2003-05-14
IL157659A0 (en)	2004-03-28
SI1373224T1 (sl)	2007-10-31
CZ20032451A3 (cs)	2004-09-15
CY1106829T1 (el)	2012-05-23
CA2441313A1 (fr)	2002-09-26
IL157659A (en)	2008-08-07
EA200300906A1 (ru)	2004-02-26
BR0208192A (pt)	2004-03-02
HUP0303637A2 (hu)	2004-03-01
EA006815B1 (ru)	2006-04-28
OA12454A (en)	2004-09-30
CA2441313C (fr)	2009-03-31
SV2003000925A (es)	2003-05-20
HRP20030740A2 (en)	2005-06-30
DE60221233D1 (de)	2007-08-30
SK11562003A3 (sk)	2005-01-03

Publication	Publication Date	Title
EE200300459A (et)	2004-02-16	Uued spirotritsüklilised derivaadid ja nende kasutamine fosfodiesteraas-7 inhibiitoritena
FR12C0019I2 (fr)	2013-08-16	O-cyclopropyle-carboxanilides et leur utilisation comme fongicides
AR028253A1 (es)	2003-04-30	Inhibidores de la glucogeno fosforilasa
FR13C0003I2 (fr)	2015-11-20	Inhibiteurs cycliques de proteine tyrosine kinase
AR028576A1 (es)	2003-05-14	Derivados de b-carbolina utiles como inhibidores de fosfodiesterasa
ATE269327T1 (de)	2004-07-15	Imidazol-5-yl-2-anilino-pyrimidine als inhibitoren der zellproliferation
PT1370553E (pt)	2006-09-29	Inibidores de rhoquinase
EP1583997A4 (fr)	2010-03-24	Elimination de photoresine
MA27230A1 (fr)	2005-02-01	Derives d'aminoindazoles comme inhibiteurs de proteines-kinase
NO20041293L (no)	2004-05-27	Alkyn-aryl-fosfodiesterase-4-inhibitorer
IS6656A (is)	2002-12-17	Útskiptar kínasólínafleiður og notkun þeirra sem hemla
AR028575A1 (es)	2003-05-14	Derivados de pirrolopiridinona utiles como inhibidores de fosfodiesterasa
DE60103974D1 (de)	2004-07-29	Gyrase-inhibitoren und ihre verwendung
CY2012026I2 (el)	2015-08-05	Παραγωγα κουιναζολινης ως αναστολεις vegf
MA25916A1 (fr)	2003-10-01	Nouveaux thiadiazoles et oxadiazoles et leur utilisation comme inhibiteurs de la phosphodiesterase-7
EP1534268A4 (fr)	2006-11-02	Inhibiteurs de la tyrosine kinase
EP1660436A4 (fr)	2006-11-22	Inhibiteurs de la cathepsine
DZ3357A1 (fr)	2001-11-22	Nouveaux médicaments composés de dibenzoazulène comme inhibiteurs de facteur onconécrosant
ATE264108T1 (de)	2004-04-15	Endoparasitizide gelzusammensetzung
AR028068A1 (es)	2003-04-23	Nuevos derivados de 1,1-dioxotiocromano y su uso como inhibidores de trombina
DZ3367A1 (fr)	2001-12-13	Derives de 2-aminothiazoline et leur utilisation comme inhibiteurs de no-synthase
DE60031450D1 (de)	2006-11-30	Polymorph v von torasemid
DE60007360T2 (de)	2004-10-07	Amorphe modifikation von torasemid
EE200200389A (et)	2003-10-15	Imidasooli uued derivaadid
AR028075A1 (es)	2003-04-23	Inhibidores de la peptido-desformilasa